Last reviewed · How we verify
Fentanyl Ethypharm
Fentanyl is a synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and sedation.
Fentanyl is a synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and sedation. Used for Moderate to severe pain (acute or chronic), Cancer pain.
At a glance
| Generic name | Fentanyl Ethypharm |
|---|---|
| Sponsor | Ethypharm |
| Drug class | Opioid analgesic |
| Target | Mu-opioid receptor (OPRM1) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 3 |
Mechanism of action
Fentanyl acts as a potent mu-opioid receptor agonist, activating inhibitory pathways in the spinal cord and brain that reduce pain signal transmission and perception. The Ethypharm formulation is a pharmaceutical development of this well-established opioid, likely designed to optimize delivery, bioavailability, or safety profile compared to existing fentanyl products.
Approved indications
- Moderate to severe pain (acute or chronic)
- Cancer pain
Common side effects
- Respiratory depression
- Constipation
- Nausea
- Dizziness
- Sedation
- Dependence/addiction risk
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fentanyl Ethypharm CI brief — competitive landscape report
- Fentanyl Ethypharm updates RSS · CI watch RSS
- Ethypharm portfolio CI